Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by 99942Apophison Sep 25, 2022 9:10pm
325 Views
Post# 34985537

RE:Photodynamic Therapy Market Size, Report 2022 to 2030

RE:Photodynamic Therapy Market Size, Report 2022 to 2030Oden6570 wrote 
Photodynamic Therapy Market Size, Share, Growth, Trends, Report 2022 to 2030 | BioSpace


Excellent find Oden6570 I wonder how many patients currently returning for their BCG just like our Gooseybear has to and are these people currently devoted to that treatment or will they be flocking over to TLD-1433 for 1 or 2 and done treatments.  In my opinion once available to the public Theralase will be treating not only unresponsive but also the ones having to return over & over again for continued BCG treatments to the point that with SOC designation given to Theralase's TLD-1433 in a few short years will be referred to as the dominant treatment worldwide. 
Who was it that foresaw the share price on this board around 700 dollars will be called one with incredible foresight but that $700 mark could take a few years after commercialization has begun. 
<< Previous
Bullboard Posts
Next >>